Tropocells® is the optimal cost-effective measure
in the prevention of sternal wound infections following cardiac surgery

The use of autologous platelet gel in cardiac surgery provides significant reductions in both deep and soft sternal wound infections.

Deep sternal wound infection following cardiac surgery is a global life-threatening complication. Sternal wound infections after cardiac surgery procedures increase mortality and overall associated cost.

. It has been shown that autologous platelet rich plasma (PRP) and platelet rich fibrin (PRF) derived from the patient’s own blood has been used to promote successful wound healing in cardiac tissue regeneration in patients undergoing sternotomy for cardiac surgical procedures. Deep sternal wound infection following cardiac surgery can be easily reduced by topical application of autologous platelet rich plasma and fibrin gel matrix.

Using the Tropocells® PRP and PRF technology helps decreasing  the incidence and costs of sternal wound complications following cardiac surgery.

Tropocells® PRP is applied inside the sternotomy wound before closure.


Neutrophil-poor PRP


FDA cleared 510(k) Class II medical device: Tropocells PRP is intended for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft or allograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK110035

Close Menu